You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

Parke Davis Company Profile

✉ Email this page to a colleague

« Back to Dashboard

What is the competitive landscape for PARKE DAVIS, and what generic and branded alternatives to PARKE DAVIS drugs are available?

PARKE DAVIS has one hundred approved drugs.

Summary for Parke Davis

US Patents:	0
Tradenames:	72
Ingredients:	64
NDAs:	100

Drugs and US Patents for Parke Davis

+ Get email alerts for changes to this table

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Parke Davis	TOLBUTAMIDE	tolbutamide	TABLET;ORAL	086047-001	Approved Prior to Jan 1, 1982		DISCN	No	No		⤷ Subscribe				⤷ Subscribe
Parke Davis	CHLORDIAZEPOXIDE HYDROCHLORIDE	chlordiazepoxide hydrochloride	CAPSULE;ORAL	084598-001	Approved Prior to Jan 1, 1982		DISCN	No	No		⤷ Subscribe				⤷ Subscribe
Parke Davis	METHYLDOPA AND HYDROCHLOROTHIAZIDE	hydrochlorothiazide; methyldopa	TABLET;ORAL	071899-001	Nov 23, 1987		DISCN	No	No		⤷ Subscribe				⤷ Subscribe
Parke Davis	EUTHROID-1	liotrix (t4;t3)	TABLET;ORAL	016680-002	Approved Prior to Jan 1, 1982		DISCN	No	No		⤷ Subscribe				⤷ Subscribe
Parke Davis	BENYLIN	diphenhydramine hydrochloride; pseudoephedrine hydrochloride	SOLUTION;ORAL	019014-001	Jun 11, 1985		DISCN	No	No		⤷ Subscribe				⤷ Subscribe
Parke Davis	CHLOROMYXIN	chloramphenicol; polymyxin b sulfate	OINTMENT;OPHTHALMIC	050203-002	Approved Prior to Jan 1, 1982		DISCN	No	No		⤷ Subscribe				⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for Parke Davis

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Parke Davis	CEREBYX	fosphenytoin sodium	INJECTABLE;INJECTION	020450-001	Aug 5, 1996	4,260,769	⤷ Subscribe
Parke Davis	CHOLYBAR	cholestyramine	BAR, CHEWABLE;ORAL	071621-001	May 26, 1988	4,778,676	⤷ Subscribe
Parke Davis	CEREBYX	fosphenytoin sodium	INJECTABLE;INJECTION	020450-001	Aug 5, 1996	4,925,860	⤷ Subscribe
Parke Davis	FEMPATCH	estradiol	FILM, EXTENDED RELEASE;TRANSDERMAL	020417-001	Dec 3, 1996	5,006,342	⤷ Subscribe
Parke Davis	FEMPATCH	estradiol	FILM, EXTENDED RELEASE;TRANSDERMAL	020417-001	Dec 3, 1996	4,906,463	⤷ Subscribe
Parke Davis	CHOLYBAR	cholestyramine	BAR, CHEWABLE;ORAL	071739-001	May 26, 1988	4,778,676	⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Paragraph IV (Patent) Challenges for PARKE DAVIS drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Sublingual Tablets	0.3 mg, 0.4 mg and 0.6 mg	➤ Subscribe	2005-10-19
➤ Subscribe	Sublingual Tablets	0.6 mg	➤ Subscribe	2011-12-29

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.